Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial - Top-Institutions - MDSpire

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial

  • By

  • Richard E. Pratley

  • Douglas Scott Denham

  • Rupal Trivedi

  • Elaine Watkins

  • Lisa Connery

  • Jennifer Barnes

  • Dongzi Yu

  • Janet Hong

  • Christopher Simard

  • Kimberly Umans

  • Lan Liu

  • Giridhar S. Tirucherai

  • Jing L. Marantz

  • June 8, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    NewYork-Presbyterian Hospital/Weill Cornell Medicine
    NewYork-Presbyterian Hospital/Weill Cornell Medicine

    New York, NY

    Key Differentiators

    • Endocrinology
    • Obesity Medicine

  • #2

    Northwestern Medicine – Northwestern Memorial Hospital/Feinberg School of Medicine
    Northwestern Medicine – Northwestern Memorial Hospital/Feinberg School of Medicine

    Chicago, IL

    Key Differentiators

    • Endocrinology
    • Obesity Medicine

Original Source(s)

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial

  • by Richard E. Pratley, Douglas Scott Denham, Rupal Trivedi, Elaine Watkins, Lisa Connery, Jennifer Barnes, Dongzi Yu, Janet Hong, Christopher Simard, Kimberly Umans, Lan Liu, Giridhar S. Tirucherai, Jing L. Marantz

  • June 8, 2026

Related Content

Understanding Weight Regain After Tirzepatide Withdrawal

NLR inflammasome pathways: key targets for pathogenesis and therapy of metabolic diseases

Nonlinear association between serum insulin, visceral fat area, and kidney function in female with type 2 diabetes: a retrospective study